Pharma & M&A
Amneal Pharma Acquisition: A Massive Bet on Biosimilars
What’s happening
Amneal Pharmaceuticals today (April 22, 2026) announced a definitive agreement to acquire Kashiv BioSciences in a transaction valued at up to $1.1 billion. The deal involves $375 million in cash and $375 million in equity upfront, with an additional $350 million tied to regulatory and commercial milestones.
What’s changing / Business impact
-
Strategic Integration: Amneal is transforming into a fully integrated global biosimilars leader, combining Kashiv’s R&D and manufacturing with its own commercial scale.
-
LOE Capitalization: The deal is timed to hit just before a projected $300B wave of global biologic loss-of-exclusivity (LOE) over the next decade.
-
Portfolio Expansion: By 2030, Amneal expects to have more than 12 commercial biosimilars and over 20 additional products in its development pipeline.
Why this matters
The next phase of pharma growth is not just about breakthrough innovation, it’s about cost competition.
This move highlights several key shifts:
-
Biosimilars have shifted from niche experiments to a core strategic priority for diversified drugmakers.
-
Sustained pricing pressure from payers is forcing portfolios to favor high-volume, cost-efficient alternatives.
-
Future market leadership will be defined by the ability to offer affordability at a massive manufacturing scale.